ESR1 and cancer: A well-established link exists between high genomic instability and TP53 mutations and resistance to cancer treatment; however, we are the first to our knowledge to show that primary estrogen receptor (ER)–positive tumors with high genomic instability have an intrinsic resistance to treatment that can be measured after a short, 2-week AI treatment.